Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 11/3030% below fair value
$6.08+0.17 (+2.88%)
Close on Nov 13, 2026Market cap $11.71MP/E –Yield –
Bolt Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Bolt Biotherapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $21.50M, down 49.4% year over year. For fiscal 2025 it was $28.53M, down 50.4% from the year before. The highest annual figure on record is $75.66M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.53M | -50.4% |
| FY2024 | Dec 31, 2024 | $57.47M | -6.6% |
| FY2023 | Dec 31, 2023 | $61.54M | -15.8% |
| FY2022 | Dec 31, 2022 | $73.12M | -3.3% |
| FY2021 | Dec 31, 2021 | $75.66M | +87.5% |
| FY2020 | Dec 31, 2020 | $40.36M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.15M | -31.3% |
| Q1 FY2026 | Mar 31, 2026 | $4.83M | -49.2% |
| Q4 FY2025 | Dec 31, 2025 | $4.99M | -57.4% |
| Q3 FY2025 | Sep 30, 2025 | $6.54M | -52.6% |
| Q2 FY2025 | Jun 30, 2025 | $7.50M | -51.4% |
| Q1 FY2025 | Mar 31, 2025 | $9.51M | -42.5% |
| Q4 FY2024 | Dec 31, 2024 | $11.72M | -28.2% |
| Q3 FY2024 | Sep 30, 2024 | $13.79M | -7.8% |
| Q2 FY2024 | Jun 30, 2024 | $15.43M | -1.3% |
| Q1 FY2024 | Mar 31, 2024 | $16.53M | +13.0% |
| Q4 FY2023 | Dec 31, 2023 | $16.32M | -3.1% |
| Q3 FY2023 | Sep 30, 2023 | $14.95M | -21.2% |
| Q2 FY2023 | Jun 30, 2023 | $15.64M | -17.3% |
| Q1 FY2023 | Mar 31, 2023 | $14.63M | -20.5% |
| Q4 FY2022 | Dec 31, 2022 | $16.85M | -25.1% |
| Q3 FY2022 | Sep 30, 2022 | $18.97M | -1.9% |
| Q2 FY2022 | Jun 30, 2022 | $18.92M | -4.0% |
| Q1 FY2022 | Mar 31, 2022 | $18.39M | +30.1% |
| Q4 FY2021 | Dec 31, 2021 | $22.48M | +51.3% |
| Q3 FY2021 | Sep 30, 2021 | $19.34M | +102.7% |
| Q2 FY2021 | Jun 30, 2021 | $19.71M | +115.0% |
| Q1 FY2021 | Mar 31, 2021 | $14.13M | +108.1% |
| Q4 FY2020 | Dec 31, 2020 | $14.86M | – |
| Q3 FY2020 | Sep 30, 2020 | $9.54M | – |
| Q2 FY2020 | Jun 30, 2020 | $9.17M | – |
| Q1 FY2020 | Mar 31, 2020 | $6.79M | – |
See a number that looks wrong?